Featuring all Hallmarks of Cancer



Complex biologies, intelligently simplified.







clara^T is a unique software-driven solution, classifying biologically relevant gene expression signatures into a comprehensive, easy-to-interpret report.

clara^T benefits at a glance:

- Maximises the understanding of your dataset
- Provides readouts for the most relevant published gene expression signatures
- Standardises comparisons between different datasets
- Highlights consensus between multiple gene expression signatures
- Provides extensive supplementary data for innovative analysis
- Multiple signatures from a single tumour sample
- Cost effective solution, saving analysis time

The opportunity created by RNA-Sequencing:

- RNA-Sequencing (RNA-Seq) is an untapped resource for biomarker discovery and development in oncology enabling the discovery and validation of an endless combination of gene expression signatures
- Gene expression signatures are more dynamic than DNA based biomarkers and better reflect changes in biology as a tumour adapts to multiple treatments
- RNA-Seq can also be used for detection of novel gene fusions and alternative transcripts



Hannah Millar, Senior Laboratory Scientist

The challenges of RNA-Sequencing:

However, there are some inherent challenges with high throughput RNA-Seq. These include:

- Complex data outputs that require advanced computational bioinformatics pipelines to develop and validate robust gene expression assays
- Analysis of multiple signatures and biologies can be time consuming, requiring significant bioinformatics / statistical resource
- There are still no PMA approved gene expression assays creating a potential regulatory risk for companies considering this approach

clara^{T*} Report:

clara^T is a unique reporting solution to help cancer researchers overcome the challenges associated with RNA-Seq and analysis. Samples can be sent to Almac's Labs for processing and automated generation of the clara^T report.

clara^T classifies publicly available gene expression signatures and single gene targets linked to multiple key biologies, alongside Almac's own proprietary assays, according to the 10 Hallmarks of Cancer. Originally published by Douglas Hanahan and Robert Weinberg in 2000. Clients are provided with a unique, interactive report that allows the easy visualisation of the key discriminating biologies within both the study cohort and an individual tumour sample.

A pan-cancer solution, based on a powerful bioinformatics pipeline, automatically generating the clara^T report from raw gene expression data utilising our Next Generation Sequencing (NGS) service.

* clara^T is for research use only (RUO) and is not to be used for diagnostic or prognostic purposes, including predicting responsiveness to a particular therapy

clara[™] - Utilising the Hallmarks of Cancer:

First conceptualised by Douglas Hanahan and Robert Weinberg in 2000 and subsequently updated in 2011, the **Hallmarks of Cancer** have become a paradigm within modern cancer research. The hallmarks help explain the complexity of cancer cells and describe the processes that occur allowing cancer cells to proliferate and grow if unchecked. The clara^T report utilises the Hallmarks of Cancer concept of targetable biologies to help facilitate biomarker discovery. clara^T embodies the tenets set out by the authors, intelligently simplifying the complex biologies of cancer within key hallmarks.



Image adapted from The Hallmarks of Cancer. Originally published in Cell 144, Hanahan D & Weinberg RA, Hallmarks of Cancer: The Next Generation, 646-674, © 2011. With permission from Elsevier.

clara[⊤] Report – Facts:



clara^T content:



Immuno-Oncology

- 14 signatures
- Almac I-O Assay
- 5 x TCGA Subgroups
- 2 x TILs Signatures
- 2 x Immune **Resistance Signatures**
- 1 x IFNy Signature • 1 x TGFβ Signature

• 1 x T-cell Signature

- 1 x Immune
- **Enrichment Score**



Inflammation

- 10 signatures • 4 x Macrophage Signatures
- 2 x NFkβ Signatures
- 2 x Inflammatory
- **Response Signatures**
- 1 x IL1β Signature • 1 x Inflammatory
- **Response Enrichment** Score

• 1 x STAT3 Signature

Enrichment Score

• 1 x PI3K/AKT



EMT

12 signatures

- Almac EMT Assay • 5 x EMT Pan-Can
- Signatures
- 2 x Stromal Signatures
- 1 x MAPK Activity
- 1 x Mesenchymal Subgroup
- 1 x MEK Functional
- 1 x EMT Enrichment Score



Genome Instability

- 10 signatures Almac DNA Damage Assay
- 2 x BRCA Signatures
- 2 x DDR Signatures
- 2 x Chromosomal

Angiogenesis

Almac Angio Assay

• 4 x Angio Subgroup

• 1 x Hypoxia Signature

Proliferation Signature

9 signatures

• 1 x Vascular

- Instability Signatures
- 1 x DNA Damage

Proliferation

- **10 signatures** • 2 x HER2 Signatures
- 2 x EGFR Signatures
- 2 x MAPK Activity
- 1 x KRAS Signature
- 1 x MYC Activity



Energetics

8 signatures

- 3 x Glycolysis Signatures
- 2 x Hypoxia Signatures
- 1 x Metabolic **Progression Signature**
- 1 x Fatty Acid Metabolism Signature • 1 x Oxidative
 - Phosphorylation **Enrichment Score**



7 signatures

- 2 x E2F Regulation Signatures
- 1 x RB-loss Signature
- 1 x TP53 Signature
- 1 x G2M Checkpoint **Enrichment Score**

Cell Death 7 signatures

- 2 x TNFα Signatures
- 1 x TP53 Signature
- 1 x TRAIL Activity
- 1 x Apoptosis Pathway Signature
- 1 x Autophagy Pathway Signature
- 1 x Apoptosis **Enrichment Score**



5 signatures

- 4 x Senescence Signatures
- 1 x Telomerase Signature

- **Evading Growth**
 - - - Signature
 - 1 x CDK4 Classifier

- 1 x Cell Cycle

- 1 x HRD Signature
- 1 x MSI Signature
- **Enrichment Score**

• 1 x Angio Predictive Signature

• 1 x Angio Enrichment

Score

clara[™] Cohort Report:


The clara^T Cohort Report and interactive heat map simplifies visualisation of expression levels across a range of the most relevant published multigene signatures allowing for quick and easy interpretation of results relating to each Hallmark of Cancer.


Supplementary files are also included in the report and are hyperlinked within each profile for additional data functionality.

Advantages of the clara^T Cohort Report:

- Discover patterns of gene expression within your cohort
- Identify unique molecular subgroups within your dataset
- Determine groups of consensus gene expression signatures
- Highlight any differences or unexplained anomalies between samples

Almac Diagnostic Services 19 Seagee Industrial Estate Craigwon 8743 505 County Armagh, MK Tel: +44 (2) 28 3833 7575 Fac: +44 (2) 28 3833 7575 Fac: +44 (2) 28 3833 7575 fac: +44 (2) 28 3830 9675 der strussort fullverer om com	Q clara"
	Client Information & Cohort Demographics
Customer Cohort ID	
clara [*] Project ID (ADXYY20XX)	ADX
Total No. of Samples	
Date Samples Received (DD/MMM/YYYY) e.g. 01 JAN 2018	
Histology of Primary Disea	ise
Site of Collection Tick as appropriate	Primary Metastatic
No. of Samples	
Sample Format Tick as appropriate	FFPE FF Blood Cell Lines
No. of Samples	
Client Contact:	
Company/Institute:	
Castomer Support - If you require an at +64 (0) 28 888 988 7575 (09:00-17	ny farsher information or assistance please contact. Almac Dispositic Services clara ⁴ Customer Support 10 SMT, 7 days per week) or <u>claratementifisionaremen com</u>
Research Use Only: The prognostic pur	e information provided within this report should not be used for diagnostic or poses, including predicting responsiveness to a particular therapy.
Verden 1.60 der #2019 (Erser Siegende Bro	ALMAC
	Permissi Manar Sara Malh






clara^T Sample Report:

The **clara^T Sample Report** gives greater insight into an individual sample and allows more detailed investigation of expression levels across signatures and single gene targets within a particular Hallmark of Cancer.

Advantages of the clara^T Sample Report:

- Determine the biological profile of your sample relative to the full cohort
- Define the underlying biology of your sample relative to a reference database
- Identify the most relevant gene expression signature / biology for your sample
- Identify key pathways of activity or repression in individual samples





	Immuno- Oncology Example	
Research Use Only Immuno-Oncology Profile 14 gene expression signatures providing insight into the molecular subgroup of samples within immune classifications, immune checkpoint target expression and phenotypic activity of turnour infiftrating hymphocytes.		Continuous signature scores/expression relative to the tested cohort
AVOIDING IMMUNE DESTRUCTION Signature Scores relative to <u>Tested Cohort 1.0 Tumour Score Tumour Score Tumour Score Tumour Score Tumour Score Tumour Score </u>		Continuous signature scores/expression relative to a reference database (TCGA)
Almac I-O Assay ^{1,2} TiLs Exhausted T-cells ³ TiLs-related GS ⁴ T-cell inflamed GEP ^{3*} IPRES Signature ⁶ TCGA CSF1 response ^{3*} TCGA Lymphocyte Infiltration ^{4*}		
TCGA TGFβ Signature** TCGA IFNY Signature** TCGA Fibroblast CSR ^{11*} TGFβ Response Signature ¹³ CTLA4 Response Signature ¹³ Immune Response (T-cells) ¹⁴ Immune Enrichment Score ^{15,16*}		Signature & single gene expression represented by graduated sliding bars
Single Gene Targets CTLA4 expression PDL1 expression LAG3 expression TIM3 expression		Darker shading represents increased expression or activation
OX40 expression ICOS expression CD27 expression IDO1 expression		
Version 1.8.8 dars ² 2019 (Almost Diagonatic Services)		Lighter shading represents decreased expression or repression

clara[⊤] benefits:

1

0

Maximises the understanding of your data set - Enables you to instantly find the most important patterns from your RNA-Seq data that will inform your research going forward.

Provides readouts for the most relevant published gene expression signatures -

Easy-to-interpret gene expression scores are displayed in the report for the most important signatures published in leading cancer journals. Providing instant information on how they perform in your dataset.

Standardises comparisons between different

datasets - By providing reproducible Hallmark classifications in an automated fashion, data analysis is standardised across multiple cohorts, removing variation between different discovery approaches.

Highlights consensus between multiple

gene expression signatures – The ability to simultaneously visualise multiple different gene expression signature readouts enables a consensus analysis approach resulting in greater confidence in data interpretation. Provides extensive supplementary data for more innovative analysis – The supplementary data files allow researchers to spend less time on routine exploratory analysis. Allowing additional focus on novel insights through integration of signature outputs to analytics tools and clinical databases, facilitating more innovative biomarker research.

0

0

Multiple signatures from a single tumour sample – A single sample sent to Almac for profiling, sequenced on an optimised NGS technology platform, with a powerful bioinformatics pipeline producing multiple signature readouts. Saving precious tissue samples, time and cost.


Cost effective solution, saving analysis

time - Cancer researchers can benefit from detailed, actionable analysis of RNA-Seq data from the report without investing in additional significant time and resource to perform in-house bioinformatics exploratory analysis.




Cain Diver, Laboratory Scientist

clara^T workflow:



clara^T reports can be generated from samples profiled by RNA-Sequencing at Almac labs or alternatively from gene expression data you may already have generated from your study cohort.





How to order clara^T:

Call | Speak to a Business Development Manager | Contact us online

- Go to the Almac Diagnostic Services' **website** www.almacgroup.com/diagnostics
- Click on the $\mathbf{clara}^{\!\!\mathsf{T}}\,\mathbf{page}$ and fill in the $\mathbf{contact}\,\mathbf{us}$ form
- One of our Business Development Managers will be in touch to discuss your requirements
- Almac Diagnostic Services will send a **quotation based on your specific requirements**
- If proceeding, complete the scope of work and sample manifest, sign the T&Cs and return to claratsupport@almacgroup.com
- A primary point of contact will be assigned to you for the duration of your project



About Almac Diagnostic Services:

Almac Diagnostic Services is a global stratified medicine company specialising in biomarker driven clinical trials, with laboratories in the UK, USA and a partner laboratory based in China.

As part of the wider Almac Group, we are a stable, privately owned business that is growing globally in line with increased customer demand. Our diagnostic experience spans oncology, immunology, CNS and infective diseases.

Want to know more about how clara^T can help your biomarker discovery and translational research?

almacgroup.com

GET IN TOUCH

Global HQ +44 28 3833 7575 **Durham, NC, USA** +1 919 294 0230